Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 17/20 | 0.65 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | HRH2 | P25021 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.45 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1179531 | 0.90 | HRH3 (0.68) | HRH3CHRM2CHRM1ADRA2CCHRM3 | |
| SCHEMBL1179240 | 0.84 | HRH3 (0.73) | HRH3CHRM2CHRM1ADRA2CCHRM3 | |
| SCHEMBL1179508 | 0.83 | HRH3 (0.71) | HRH3CHRM2CHRM1ADRA2CCHRM3 | |
| SCHEMBL15372527 | 0.79 | HRH3 (1.00) | HRH3CHRM2CHRM1ADRA2CCHRM3 | |
| SCHEMBL1178822 | 0.79 | HRH3 (1.00) | HRH3CHRM2CHRM1ADRA2CCHRM3 | |
| SCHEMBL1179419 | 0.79 | HRH3 (1.00) | HRH3CHRM2CHRM1ADRA2CCHRM3 | |
| SCHEMBL2937597 | 0.79 | HRH3 (0.67) | HRH3CHRM2CHRM1ADRA2CCHRM3 | |
| Bromide SCHEMBL1180478 | 0.78 | HRH3 (0.98) | HRH3CHRM2CHRM1ADRA2CCHRM3 | |
| Hydrochloric Acid SCHEMBL1179495 | 0.78 | HRH3 (0.98) | HRH3CHRM2CHRM1ADRA2CCHRM3 | |
| Hydrochloric Acid SCHEMBL2989255 | 0.78 | HRH3 (0.98) | HRH3CHRM2CHRM1ADRA2CCHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2221298-B1 | PHENYLPYRAZOLE DERIVATIVES | TAISHO PHARMACEUTICAL CO LTD (JP) | 2013-11-06 | — | — | EP | claimed |
| US-20100267687-A1 | PHENYLPYRAZOLE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2010-10-21 | — | — | US | claimed |
| EP-2221298-A1 | PHENYLPYRAZOLE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2010-08-25 | — | — | EP | claimed |
| EP-2221298-B1 | PHENYLPYRAZOLE DERIVATIVES | TAISHO PHARMACEUTICAL CO LTD (JP) | 2013-11-06 | — | — | EP | disclosed |
| US-8193176-B2 | Phenylpyrazole derivatives | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2012-06-05 | — | — | US | disclosed |
| US-8193176-B2 | Phenylpyrazole derivatives | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2012-06-05 | — | — | US | disclosed |
| US-8193176-B2 | Phenylpyrazole derivatives | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2012-06-05 | — | — | US | disclosed |
| US-8183387-B2 | Phenylpyrazole derivatives | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2012-05-22 | — | — | US | disclosed |
| US-8183387-B2 | Phenylpyrazole derivatives | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2012-05-22 | — | — | US | disclosed |
| US-8183387-B2 | Phenylpyrazole derivatives | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2012-05-22 | — | — | US | disclosed |
| US-20110065668-A1 | PHENYLPYRAZOLE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-03-17 | — | — | US | disclosed |
| US-20110065668-A1 | PHENYLPYRAZOLE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-03-17 | — | — | US | disclosed |
| US-20110065667-A1 | PHENYLPYRAZOLE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-03-17 | — | — | US | disclosed |
| US-7888354-B2 | Phenylpyrazole derivatives | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2011-02-15 | — | — | US | disclosed |
| US-7888354-B2 | Phenylpyrazole derivatives | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2011-02-15 | — | — | US | disclosed |
| US-7888354-B2 | Phenylpyrazole derivatives | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2011-02-15 | — | — | US | disclosed |
| US-20100267687-A1 | PHENYLPYRAZOLE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2010-10-21 | — | — | US | disclosed |
| US-20100267687-A1 | PHENYLPYRAZOLE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2010-10-21 | — | — | US | disclosed |
| US-20100267687-A1 | PHENYLPYRAZOLE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2010-10-21 | — | — | US | disclosed |
| EP-2221298-A1 | PHENYLPYRAZOLE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2010-08-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065668-A1 | PHENYLPYRAZOLE DERIVATIVES | PER2, CRY1, HCRTR1 | HRH3 5/4885CHRM2 310/4885CHRM1 214/4885 |
| US-20110065667-A1 | PHENYLPYRAZOLE DERIVATIVES | PER2, CRY1, HCRTR1 | HRH3 5/4885CHRM2 310/4885CHRM1 214/4885 |
| US-20100267687-A1 | PHENYLPYRAZOLE DERIVATIVES | PER2, CRY1, HCRTR1 | HRH3 5/4885CHRM2 310/4885CHRM1 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.